A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)

Next Previous
Trial Profile

A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2018

At a glance

  • Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
  • Indications Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Human papillomavirus infections; Vulvovaginal cancer
  • Focus Pharmacodynamics; Registrational
  • Sponsors Merck & Co; Merck Sharp & Dohme

    • Most Recent Events

    • 28 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 22 Jun 2017 Planned End Date changed from 16 Jun 2017 to 3 Aug 2017.
    • 06 Apr 2017 The trial has been completed in Spain, according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top